Bleakley Financial Group LLC Has $2.63 Million Holdings in Bristol Myers Squibb Company $BMY

Bleakley Financial Group LLC raised its stake in Bristol Myers Squibb Company (NYSE:BMY) by 29.9% during the first quarter, HoldingsChannel reports. The institutional investor owned 43,322 shares of the biopharmaceutical company’s stock after acquiring an additional 9,979 shares during the period. Bleakley Financial Group LLC’s holdings in Bristol Myers Squibb were worth $2,627,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Citizens National Bank Trust Department boosted its stake in shares of Bristol Myers Squibb by 5.4% in the 1st quarter. Citizens National Bank Trust Department now owns 26,374 shares of the biopharmaceutical company’s stock valued at $1,600,000 after purchasing an additional 1,359 shares during the last quarter. Chicago Partners Investment Group LLC boosted its position in Bristol Myers Squibb by 46.1% during the first quarter. Chicago Partners Investment Group LLC now owns 64,146 shares of the biopharmaceutical company’s stock valued at $3,772,000 after acquiring an additional 20,249 shares during the last quarter. Procyon Advisors LLC boosted its position in Bristol Myers Squibb by 17.7% during the first quarter. Procyon Advisors LLC now owns 18,187 shares of the biopharmaceutical company’s stock valued at $1,103,000 after acquiring an additional 2,735 shares during the last quarter. Global Assets Advisory LLC acquired a new stake in Bristol Myers Squibb during the 1st quarter worth about $38,000. Finally, Anchor Investment Management LLC raised its position in shares of Bristol Myers Squibb by 16.1% in the 1st quarter. Anchor Investment Management LLC now owns 13,144 shares of the biopharmaceutical company’s stock worth $797,000 after acquiring an additional 1,827 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analysts Set New Price Targets

BMY has been the subject of a number of research analyst reports. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 2nd. Guggenheim reiterated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a report on Monday, July 6th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $61.25.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Investors are focusing on Bristol Myers Squibb’s strong earnings surprise history, with recent coverage suggesting the company has the right setup to beat estimates again in its next quarterly report. Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Analysts highlighted progress in BMY’s CELMoD program, including the FDA filing for mezigdomide in relapsed or refractory multiple myeloma, which could strengthen the company’s oncology portfolio and long-term pipeline value. Can BMY’s CELMoD Program Advancements Strengthen Its Oncology Portfolio?
• Positive Sentiment: Agilent’s FDA approval for a companion diagnostic tied to Bristol Myers Squibb’s Opdivo franchise supports continued relevance for one of BMY’s key cancer drugs. Agilent Receives FDA Approval…
• Neutral Sentiment: BMY has been attracting increased user and market attention, but the coverage does not point to a specific catalyst beyond general interest in the stock. Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Wells Fargo initiated/maintained a Hold rating, signaling a cautious but not bearish view that may limit upside enthusiasm. Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo
• Negative Sentiment: MarketWatch noted that Bristol Myers Squibb underperformed peers in Tuesday trading, suggesting some relative weakness versus other healthcare stocks. Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
• Negative Sentiment: Septa Pharmaceuticals acquired CeeNU (lomustine) from Bristol Myers Squibb Canada, reflecting a divestiture of a legacy oncology asset rather than a growth driver. Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

Bristol Myers Squibb Price Performance

BMY stock opened at $58.73 on Thursday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The business has a 50-day simple moving average of $56.84 and a two-hundred day simple moving average of $57.72. The company has a market capitalization of $119.94 billion, a P/E ratio of 16.50, a price-to-earnings-growth ratio of 0.16 and a beta of 0.23. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the company earned $1.80 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.33 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.